Core Viewpoint - Huahai Pharmaceutical's subsidiary, Zhejiang Huahai Pharmaceutical Technology Co., has successfully passed an FDA inspection, confirming compliance with CGMP standards for its production facility [2]. Group 1 - The FDA conducted an on-site inspection from August 18 to August 22, 2025, focusing on the overall quality management system and oral solid dosage products of Huahai Technology [2]. - The inspection report indicates that Huahai Technology's production base meets the requirements of current Good Manufacturing Practice (CGMP) for pharmaceuticals [2].

Corporate Governance - China Aluminum announced the election of He Wenjian as chairman and the appointment of Zhang Ruizhong as general manager, effective immediately [3] - Jiang Guiting, the actual controller and chairman of Jingjin Equipment, has had his detention lifted, allowing him to resume his duties [8] - Biao Bang Co. has terminated its plans for a change in control, with stock resuming trading [7] Industry Developments - Jiangbolong reported that its self-developed main control chip deployment has exceeded 100 million units, with rapid growth expected [4] - Asia Pacific Pharmaceutical received a notice of disapproval for its consistency evaluation application for a drug, which will not significantly impact its current performance [5] - Fuxiang Pharmaceutical successfully passed a cGMP inspection by the FDA, marking its third successful inspection [6] - Huahai Pharmaceutical's subsidiary passed an FDA inspection, enhancing its international market capabilities [13] Financial Performance - Daqin Railway reported a cargo transport volume of 32.51 million tons in October 2025, a year-on-year decrease of 4.7% [18] - Jingji Zhino achieved sales revenue of 317 million yuan from selling 233,300 pigs in October 2025 [19] - Baiyun Airport reported a passenger throughput of 7.64 million in October 2025, a year-on-year increase of 12.04% [20] - Dongfeng Motor's total vehicle production in October 2025 was 6,536 units, a year-on-year decrease of 23.40% [21] - Hongyang Real Estate reported a contract sales amount of 202 million yuan in October 2025 [22] Shareholder Actions - Xintonglian announced that a shareholder plans to reduce its stake by up to 3% [24] - Tonghua Dongbao conducted its first share buyback, acquiring 143,500 shares for 1.29 million yuan [25] - Guoci Materials plans to repurchase shares worth 100 million to 200 million yuan at a price not exceeding 30 yuan per share [26] Project Wins - Dayu Water-saving announced a pre-bid win for a 310 million yuan water conservancy project in Hainan [28] - Zhongjian Technology signed a significant sales contract worth 563 million yuan [29] - Longjian Co. won a project bid worth 441 million yuan for road construction in Heilongjiang [30] - Chongqing Construction's subsidiary won a project bid worth 781 million yuan for a residential project in Chongqing [31]

Core Viewpoint - Huahai Pharmaceutical's subsidiary, Zhejiang Huahai Pharmaceutical Technology Co., Ltd., successfully passed an FDA inspection, confirming compliance with current Good Manufacturing Practices (CGMP) for drug production [1] Group 1 - The FDA inspection took place from August 18 to August 22, 2025, covering the overall quality management system and oral solid dosage products of the factory [1] - The inspection report indicates that the production base of Huahai Technology meets the requirements of CGMP [1]

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 号 2025-115 | | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | 浙江华海药业股份有限公司 关于子公司通过美国 FDA 现场检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下简称"公司"）子公司浙江华海制药科技有限 公司（以下简称"华海科技"）于 2025 年 8 月 18 日至 2025 年 8 月 22 日接受了美国 食品药品监督管理局（以下简称"FDA"）的现场监督检查，检查范围涵盖工厂整体 质量管理体系及口服固体制剂产品。近日，公司收到现场检查报告，该报告表明华海 科技生产基地符合美国药品 CGMP（现行药品生产质量管理规范）要求，通过了本次 现场检查。现将相关信息公告如下： 由于医药产品具有高科技、高风险、高附加值的特点，各类投产后的产品未来的 具体销售情况可能受到市场环境变化等因素影响，具有较大不确定性，敬请广大投资 1 ...

Core Viewpoint - Huahai Pharmaceutical's subsidiary, Zhejiang Huahai Pharmaceutical Technology Co., Ltd., successfully passed the FDA's on-site inspection, confirming compliance with current Good Manufacturing Practices (CGMP) for drug production [1] Group 1 - The FDA inspection took place from August 18 to August 22, 2025, covering the overall quality management system and oral solid dosage products of the factory [1] - The inspection report indicates that the production base of Huahai Technology meets the requirements of CGMP [1]

Core Viewpoint - Huahai Pharmaceutical's subsidiary, Zhejiang Huahai Pharmaceutical Technology Co., Ltd., successfully passed an FDA inspection, confirming compliance with current Good Manufacturing Practices (CGMP) for drug production [1] Group 1 - The FDA inspection took place from August 18 to August 22, 2025, covering the overall quality management system and oral solid dosage products of Huahai Technology [1] - The inspection report indicates that the production base of Huahai Technology meets the requirements of CGMP [1]

Core Insights - The domestic pharmaceutical market is undergoing a new round of reshuffling, with the 11th batch of national drug procurement results recently announced, covering 55 varieties and 453 products in high-demand treatment areas such as anti-infection, diabetes, and hypertension [1] - Dongyang Sunshine Pharmaceutical's loss of the bid for Oseltamivir granules, which contributed over 75% of its revenue in 2023, poses a significant threat to its core business [1] - The company's heavy reliance on hospital channels for over 80% of its sales exacerbates the impact of this loss [1] Group 1: Company Challenges - Dongyang Sunshine Pharmaceutical's product structure is notably singular, leading to a weaker ability to withstand risks compared to peers like Heng Rui Medicine, which has previously faced similar challenges [1] - The company has over 100 products in research across infection, chronic disease, and oncology, indicating a desire for transformation, but significant concerns remain regarding the feasibility of this strategy [1][2] Group 2: Research and Development Issues - The company's R&D investment is characterized by a "high proportion, low absolute value," with R&D expenses of 348 million yuan in the first half of 2025, only one-tenth of Heng Rui's during the same period [2] - The broad but shallow pipeline in the infection sector faces competition from Roche's new drug Marbofloxacin, while insulin products in the chronic disease sector yield low profits despite winning bids [2] - The oncology drug Crizotinib is still in phase three clinical trials, lagging behind competitors, highlighting the company's insufficient R&D capabilities and funding reserves [2] Group 3: Industry Context - Dongyang Sunshine Pharmaceutical's predicament reflects the broader challenges faced by Chinese pharmaceutical companies under the dual pressures of national procurement and the need for innovative transformation [2] - The loss of the bid serves as a performance warning and a survival test for companies still reliant on single-product strategies [2]

Core Viewpoint - Shanghai Mengke Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the supplementary application of the drug "Kangti Zuoan Tablets" and the clinical trial of "MRX-5 Tablets," indicating significant progress in the company's product pipeline and supply chain management [1][4]. Group 1: Kangti Zuoan Tablets - The drug "Kangti Zuoan Tablets" is a new generation oxazolidinone antibiotic developed by the company, approved for treating complex skin and soft tissue infections, and was launched in China in June 2021 [2]. - The recent approval allows Jiangsu Xuantai Pharmaceutical Co., Ltd. to be added as a contracted manufacturing enterprise, and Chongqing Boteng Pharmaceutical Technology Co., Ltd. will supply the active pharmaceutical ingredient [1][3]. - This development is crucial for ensuring stable product supply and meeting market demand, although sales are subject to policy and market environment influences [3]. Group 2: MRX-5 Tablets - "MRX-5 Tablets" is a new type of benzoborazole antibiotic intended for treating infections caused by non-tuberculous mycobacteria (NTM), with an increasing incidence and prevalence of NTM infections [5][6]. - The company has received approval to conduct further clinical trials for a new 200mg specification of MRX-5, which has shown good antibacterial activity and safety in previous trials [4][6]. - MRX-5 has completed Phase I clinical trials in Australia and has been granted orphan drug designation by the US FDA, indicating its potential in the market [6][7].

Core Points - Huahai Pharmaceutical announced that as of November 5, 2025, its stock price has fallen below 80% of the current conversion price for at least 15 trading days within any 30 consecutive trading days, triggering the downward adjustment clause for "Huahai Convertible Bonds" [2] - The company's board of directors decided not to exercise the right to adjust the conversion price downwards at this time and will not propose a downward adjustment plan if the clause is triggered again within the next two months [2] - Starting from January 6, 2026, if the downward adjustment clause is triggered again, the board will hold another meeting to decide whether to exercise the right to adjust the conversion price [2]

| | | 浙江华海药业股份有限公司 关于不向下修正"华海转债"转股价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 截至 2025 年 11 月 5 日，浙江华海药业股份有限公司（以下简称"公司"） 股价已出现任意三十个连续交易日中至少十五个交易日收盘价格低于当期转股 价格 80%的情形，触及"华海转债"转股价格向下修正条款。 经公司第九届董事会第六次临时会议审议通过，公司董事会决议本次不行使 "华海转债"转股价格向下修正的权利，且在未来 2 个月内（2025 年 11 月 6 日 至 2026 年 1 月 5 日），如再次触及可转债的转股价格向下修正条款，亦不提出向 下修正方案。从 2026 年 1 月 6 日开始重新起算，若再次触发"华海转债"转股 价格向下修正条款，届时公司董事会将再次召开会议审议是否行使"华海转债" 转股价格向下修正的权利。 一、可转换公司债券基本情况 根据中国证券监督管理委员会《关于核准浙江华海药业股份有限公司公开发 行可转换公司债券的批复》（证监许可[2020]22 ...